Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Addex Therapeutics
Biotech
J&J calls time on Addex partnership a year after epilepsy fail
Nine months after J&J stepped back from an Addex-partnered epilepsy drug in the wake of a phase 2 fail, the pharma has now severed the relationship.
James Waldron
Apr 17, 2025 7:05am
Addex stock rises after Indivior offers up to $300M for compound
Aug 27, 2024 10:50am
J&J drops Addex epilepsy drug after reviewing phase 2 failure
Jul 18, 2024 5:17am
Addex's Janssen-partnered epilepsy drug fails phase 2 trial
Apr 29, 2024 8:44am
Lonza lands new CEO—Chutes & Ladders
Apr 5, 2024 8:30am
Why do so many biotechs face being kicked off the Nasdaq?
Mar 14, 2023 9:55am
